Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer

Kiyotaka Yoha Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, JapanCorrespondence[email protected]

Shinji Atagib Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan

Martin Reckc Lungen Clinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany

Edward B. Garond David Geffen School of Medicine, University of California Los Angeles/TRIO-US Network, Los Angeles, CA, USA

Santiago Ponce Aixe Hospital Universitario, CNIO Lung Cancer Clinical Research Unit, Universidad Complutense and Ciberonc, Madrid, Spain

Denis Moro-Sibilotf Grenoble University Hospital, Grenoble, France

Katherine B. Winfreeg Eli Lilly and Company, Indianapolis, IN, USA

Bente Frimodt-Mollerh Eli Lilly and Company, Copenhagen, Denmark

Annamaria Zimmermanng Eli Lilly and Company, Indianapolis, IN, USA

Carla Visseren-Gruli Lilly Oncology, Utrecht, Netherlands

Kazuhiko Nakagawaj Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan

Your download is now in progress and you may close this window